Organ transplantation

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

Retrieved on: 
Wednesday, December 6, 2023
Research, Surgery, Hospitals, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Harold Fowler McCormick, GMP, Hope, Therapy, Northwestern University, CDMO, Transplant, Patient, Multimedia, FDA, Autoimmune disease, Cell engineering, Medical College of Wisconsin, Organ transplantation, MD, CGMP, Partnership, Doctor of Philosophy, Medical college, Phase II, Quality of life, Pharmaceutical industry

Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.

Key Points: 
  • Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
  • View the full release here: https://www.businesswire.com/news/home/20231206255985/en/
    This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform.
  • "We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options," said Cyrus Yang, COO of Taiwan Bio.
  • Our Phase 2 trial represents a significant step forward in our mission to provide solid organ transplant patients with better treatment options."

United States Regenerative Medicine Market Report 2023-2028: Robust Product Pipeline in Gene Therapies, Cell Therapies, Tissue Engineering Driving Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Pharmaceutical, Health, Regenerative medicine, Human body, Conditional sentence, Incidence, Parkinson's disease, Gene, Competition, Investment, Tissue, Genomics, Insurance, Patient, DSM-IV codes, FDA, Tissue engineering, Genetic, Genetic disorder, Organ transplantation, Burns, Development, 3D bioprinting, Quality of life, Injury, Pharmaceutical industry, Vaccine, Health care, Veterinary medicine, 3D printing, Research

The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The increasing adoption of stem cell technology, technological advancements, and a strong product pipeline are driving the demand for regenerative medicine.
  • Strong Product Pipeline: A robust product pipeline in gene therapies, cell therapies, tissue engineering, and more is driving demand for regenerative medicine.
  • Company Profiles: Detailed analysis of the major companies present in the United States Regenerative Medicine Market.

Paragonix Technologies Unveils Expansive Organ Procurement Network

Retrieved on: 
Tuesday, November 28, 2023
Cardiology, Biotechnology, Professional Services, Health, Health Technology, Medical Devices, Research, Hospitals, Surgery, Science, Finance, Transplant, Surgeon, DCD, Patient, SCTA, Pet recovery service, Ecosystem, FACS, Organ transplantation, Standard of care, Partnership, Growth, Transport, Philosophy, Dentistry

Paragonix Technologies , a pioneer in organ transplant solutions, is proud to announce the launch of a comprehensive network of donor organ procurement, preservation, and transportation services .

Key Points: 
  • Paragonix Technologies , a pioneer in organ transplant solutions, is proud to announce the launch of a comprehensive network of donor organ procurement, preservation, and transportation services .
  • Through forming key partnerships with premium logistics providers and capitalizing on our advanced preservation techniques and technologies, Paragonix guarantees reliable, timely delivery of vital resources.
  • "Optimizing every facet of a donor organ’s journey is our core mission,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.
  • As a leading transplant company, Paragonix now offers a versatile array of solutions, tailored to meet the diverse needs of organ transplantation.

Artificial Organs Global Market Report 2023: A Potential $17.7 Billion Opportunity by 2027 - Benefits of Artificial Organs Over Traditional Transplants Drive Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Hospitals, Health, Surgery, Medical Supplies, Kidney disease, COPD, Artificial organ, Prevalence, Cardiomyopathy, Investment, Liver cancer, Pelvic floor dysfunction, End organ damage, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Viral, Inflammation, Chronic obstructive pulmonary disease, Blood, Organ transplantation, Ageing, Infection, Myocarditis, Growth, Cystic fibrosis, Moyamoya disease, Organic, Accident, Sonova, LivaNova, Smoking, Blood pressure, Aquaculture, Dentistry

This report is a comprehensive study of the global artificial organs market.

Key Points: 
  • This report is a comprehensive study of the global artificial organs market.
  • It describes the artificial organs market, segmented by product type and region.
  • Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants.
  • Emerge more prepared and stay at the forefront of the global artificial organs market.

Hundreds of transplant patients, physicians, and health equity advocates join Honor the Gift rally on Capitol Hill to implore President Biden and HHS Secretary Becerra to immediately restore Medicare coverage of critical blood tests that detect organ tran

Retrieved on: 
Tuesday, December 5, 2023
Macs, Sibling, Patient, CMS, Infection, Cancer, Administration, Recurrence, Quality of life, Government, Travel, Educational Testing Service, Immune system, Organization, Multimedia, House, Heart, Health, Health equity, Society, Physician, Kidney, Immunosuppression, Risk, Transplant surgeon, ASTS, Organ transplantation, HHS, Medicare, International Society, Comment, Gift, Immunodeficiency, Lung transplantation, Dialysis, Left–right political spectrum, Fear, American Society of Transplantation, COVID-19, The Wall Street Journal, MD, Dentistry, Pharmaceutical industry, Hospital, Health insurance, Latino, Noridian Mutual Insurance Company, Policy, Transplant

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Congressman Don Bacon (R-NE-02), Senator Kirsten Gillibrand (D-NY), co-sponsors of the Living Donor Protection Act, Newt Gingrich, former Speaker of the House, Reverend Al Sharpton, civil rights and social justice leader, and Al B. Sure!, universally celebrated recording artist and liver transplant recipient, joined the Honor the Gift coalition and the American Association of Kidney Patient's (AAKP) Chair of Policy and Global Affairs Paul T. Conway, and other leaders in the field for a press conference on Capitol Hill, calling on the Centers for Medicare & Medicaid Services (CMS), Health and Human Services (HHS) Secretary Xavier Becerra, and President Joe Biden to stop the current attempt by private contractors to rollback Medicare coverage for innovative molecular blood tests for transplant patients.

Key Points: 
  • The critical tests at issue help detect organ transplant rejection early and reduce the need for invasive biopsies.
  • For example, many transplant patients receive these sequential blood tests post-transplant to monitor their transplanted organ.
  • The results of each blood test can provide a potential early warning of organ transplant rejection and injury before other indicators.
  • Especially troubling is that some of these patients who have not received testing may unknowingly be suffering from asymptomatic organ transplant rejection.

InsightRX Brings Groundbreaking Advancements in Model-Informed Precision Dosing to the ASHP Midyear Conference

Retrieved on: 
Tuesday, November 28, 2023
Carondelet Health Network, Safety, SAN, Vancomycin, Organization, Infection, Hematology, Patient, Medicine, ASHP, Data analysis, Science, Intelligence, Anticoagulant, UVM, Booth, Organ transplantation, MAP, BMI, University, Doctor of Philosophy, Body mass index, Society, Pharmaceutical industry, Medical device

SAN FRANCISCO, Nov. 28, 2023 /PRNewswire/ -- InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – today announced three major enhancements to current precision dosing solutions based on recent scientific and technological breakthroughs, as well as expansion into new therapeutic areas.

Key Points: 
  • InsightRX executives will be at Booth 566 of the American Society of Healthcare Pharmacists (ASHP) Midyear 2023 conference in Anaheim, Calif., from Dec. 3-7, to discuss these product enhancements and the science behind them.
  • InsightRX's Nova precision dosing software platform offers multiple pharmacokinetic (PK) models for dosing of vancomycin, which is used to treat and prevent bacterial infections.
  • When using model-informed precision dosing (MIPD), a measured level sometimes does not fit well with a model's predictions.
  • Come by the InsightRX booth 566 to discuss how precision dosing solutions can help advance clinical practice for your organization.

NASP Applauds the Senate Finance Committee for Taking Additional Steps to Address Anticompetitive PBM Practices

Retrieved on: 
Wednesday, November 8, 2023
National Association, Insurance, DIR, NASP, Haemophilia, Rare, Committee, Legislation, Meat extenders, Acquisition, Accreditation, Rheumatoid arthritis, Health, Maintenance, Administration, United States Senate Finance Subcommittee on Health Care, Medicare Part D, Growth, Organ transplantation, Pharmacy, Cystic fibrosis, Specialty pharmacy, Multiple sclerosis, House, Cancer, Patient, Senate, Hospital, Medicare, Medicaid

Washington, DC, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) thanks the Senate Finance Committee for its bipartisan efforts to address anticompetitive practices that ultimately harm beneficiary access to the specialty pharmacy of their choice.

Key Points: 
  • Washington, DC, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) thanks the Senate Finance Committee for its bipartisan efforts to address anticompetitive practices that ultimately harm beneficiary access to the specialty pharmacy of their choice.
  • Today’s legislation includes efforts to strengthen and enforce the long-standing federal Any Willing Pharmacy law, an NASP advocacy priority.
  • For these beneficiaries, their pharmacies meet the patients where they are in their local communities, but typically operate from a centralized location.
  • Specialty pharmacies are accredited by an independent, third party nationally recognized accreditation organization ensuring consistent quality of extensive drug management and clinical patient care services.

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Retrieved on: 
Thursday, November 2, 2023
Principal, Standard of care, United Kingdom, Trial of the century, Incidence, Tremor, EGFR, CD40L, Kidney transplantation, Banff, Glomerular filtration rate, Maintenance, Cytomegalovirus, Society, Pharmacokinetics, OLE, Hyperglycemia, Organ transplantation, ID, ATG, Webcast, Biopsy, Annual general meeting, University, Tacrolimus, Safety, Patient, Death, Hospital, Pharmaceutical industry, MD, Medicine, Eledone

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023.

Key Points: 
  • ET
    IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023.
  • There have been no cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection commonly seen with tacrolimus.
  • In September, Eledon announced that the first participant had been dosed in the Company’s Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

AlloVir Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, RSV, Immunodeficiency, Trial of the century, Respiratory syncytial virus, Viral, Congress, Data, BKV, European Society for Primary Immunodeficiencies, Investment, Patient, Organ transplantation, Pharmaceutical industry, Cryptocurrency

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023.

Key Points: 
  • AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023.
  • “At AlloVir, we are dedicated to serving immunocompromised patients suffering from devastating and life-threatening viral diseases,” said Diana Brainard, M.D., Chief Executive Officer, AlloVir.
  • Research and development expenses were $34.2 million for the quarter ended September 30, 2023, compared with $30.0 million for the quarter ended September 30, 2022.
  • General and administrative expenses were consistent at $12.8 million for the quarter ended September 30, 2023, compared with $12.9 million for the quarter ended September 30, 2022.

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023

Retrieved on: 
Monday, November 6, 2023
Interest, Cancer, Organ transplantation, Internet, Viral, SAN, Pharmaceutical industry

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m.

Key Points: 
  • SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m.
  • Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m.
  • Interested parties without internet access or unable to pre-register may dial in by calling:
    All callers should ask for the Aethlon Medical, Inc. conference call.
  • A replay of the call will be available approximately one hour after the end of the call through December 14, 2023.